ATE375400T1 - Neue mutationsmuster in hiv-1 reverser transcriptase, die mit phenotypischer resistenz gegen medikamente korrelieren - Google Patents

Neue mutationsmuster in hiv-1 reverser transcriptase, die mit phenotypischer resistenz gegen medikamente korrelieren

Info

Publication number
ATE375400T1
ATE375400T1 AT03761599T AT03761599T ATE375400T1 AT E375400 T1 ATE375400 T1 AT E375400T1 AT 03761599 T AT03761599 T AT 03761599T AT 03761599 T AT03761599 T AT 03761599T AT E375400 T1 ATE375400 T1 AT E375400T1
Authority
AT
Austria
Prior art keywords
hiv
correlate
drug
drugs
reverse transcriptase
Prior art date
Application number
AT03761599T
Other languages
English (en)
Inventor
Hilde Azijn
Bethune Marie-Pierre T M M De
Johan Vingerhoets
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Application granted granted Critical
Publication of ATE375400T1 publication Critical patent/ATE375400T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
AT03761599T 2002-07-01 2003-06-30 Neue mutationsmuster in hiv-1 reverser transcriptase, die mit phenotypischer resistenz gegen medikamente korrelieren ATE375400T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39302502P 2002-07-01 2002-07-01

Publications (1)

Publication Number Publication Date
ATE375400T1 true ATE375400T1 (de) 2007-10-15

Family

ID=30000963

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03761599T ATE375400T1 (de) 2002-07-01 2003-06-30 Neue mutationsmuster in hiv-1 reverser transcriptase, die mit phenotypischer resistenz gegen medikamente korrelieren

Country Status (6)

Country Link
EP (1) EP1520036B1 (de)
AT (1) ATE375400T1 (de)
AU (1) AU2003251731C1 (de)
CA (1) CA2490918A1 (de)
DE (1) DE60316807T2 (de)
WO (1) WO2004003227A1 (de)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997027332A1 (en) * 1996-01-26 1997-07-31 Innogenetics N.V. Method for detection of drug-induced mutations in the reverse transcriptase gene
NZ516259A (en) * 1999-05-28 2004-02-27 Virco N New mutational profiles in HIV-1 reverse transcriptase correlated with phenotypic drug resistance
BR0011939A (pt) * 1999-06-22 2002-03-12 Virologic Inc Recursos e métodos para monitorar terapia anti-retroviral inibidora de protease e orientar decisões terapêuticas no tratamento de hiv/aids
ATE422049T1 (de) * 2000-10-20 2009-02-15 Virco Bvba Festlegen von kritischen biologischen werten zur voraussage einer therapieresistenz

Also Published As

Publication number Publication date
CA2490918A1 (en) 2004-01-08
WO2004003227A1 (en) 2004-01-08
EP1520036B1 (de) 2007-10-10
AU2003251731B2 (en) 2008-09-18
EP1520036A1 (de) 2005-04-06
AU2003251731A1 (en) 2004-01-19
AU2003251731C1 (en) 2009-03-05
DE60316807T2 (de) 2008-07-17
DE60316807D1 (de) 2007-11-22

Similar Documents

Publication Publication Date Title
BR0011555A (pt) Perfis mutacionais em transcriptase reversa de hiv-1 correlacionada com resistência fenotìpica à droga
Hellard et al. Hepatitis C transmission and treatment as prevention–The role of the injecting network
Karim et al. HIV/Aids in South Africa
Hillhouse et al. Predicting in‐treatment performance and post‐treatment outcomes in methamphetamine users
ATE217105T1 (de) Verfahren und vorrichtung zur unterstützung eines benutzers zum erzeugen eines medizinischen protokolls
DE60327768D1 (de) Mutationsprofile bei mit phänotypischer medikamentenresistenz korrelierter hiv-1-protease
DE60321466D1 (de) Mit phänotypischer medikamentenresistenz korrelierte mutationsprofile in hiv-1-reverse-transkriptase
Ogawa et al. Development of hepatocellular carcinoma in patients aged 75–84 years with chronic hepatitis C treated with direct-acting antivirals
BR9911600A (pt) Recursos e métodos para monitoração de terapia antiretroviral inibidora de transcriptase reversa de não nucleosìdeo
MXPA03003476A (es) Nuevos perfiles mutacionales en transcriptasa inversa de vih-1 correlacionan con resistencia fenotipica a farmaco.
ATE375400T1 (de) Neue mutationsmuster in hiv-1 reverser transcriptase, die mit phenotypischer resistenz gegen medikamente korrelieren
Oh et al. Nurse-led computerized cognitive training for mild cognitive impairment: a preliminary study
EP1407042A4 (de) Mittel und verfahren zur überwachung einer antiretroviralen proteaseinhibitortherapie und als richtschnur für therapeutische entscheidungen bei der behandlung von hiv/aids
Hoff et al. Looking for men in all the wrong places…: HIV prevention small-group programs do not reach high risk gay men
Shrestha et al. Multiperson use of syringes among injection drug users in a needle exchange program: a gene-based molecular epidemiologic analysis
Martinello et al. Cure and Control: What Will It Take to Eliminate HCV?
KR200208239Y1 (ko) 특정인의 ｄｎａ구조를 형상화한 팔찌
Sachdeva et al. Lam Employment Absence and Productivity Scale (LEAPS): Analysis of the minimal clinically important difference (MCID) in patients with major depressive disorder using data from the CAN-BIND-1 study
BR0111575A (pt) Meios e métodos para monitorar a terapia anti-retroviral e orientar as decisões terapêuticas no tratamento de hiv/aids
Minteer et al. A DNAmCULTURE Epigenetic Fingerprint Recapitulates Physiological Aging
Guessous et al. Trends in pharmacogenomic epidemiology: 2001–2007
Nilufar Psychological characteristics of surgeons in a state of occupational stress
Kovalskaya et al. Interaction of Drugs Used for the Treatment of Cardiovascular Diseases
Mukhin et al. ANALYSIS MACE PATIENTS WITH MOKARD INFARCTION WITH ST SEGMENT ELEVATION
Schiavi et al. Early Occupational Therapy Intervention: Patients’ Occupational Needs

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1520036

Country of ref document: EP